Organization
Milestone Pharmaceuticals
6 clinical trials
Clinical trial
An Open Label Extension Study of Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular TachycardiaStatus: , Estimated PCD: 2025-04-01
Clinical trial
Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia. NODE 301 Trial.Status: Completed, Estimated PCD: 2023-01-20
Clinical trial
The NODE-202 Study Multi-Center, Multi-National, Open-Label, Efficacy and Safety Study of Etripamil Nasal Spray in Pediatric Patients With Paroxysmal Supraventricular TachycardiaStatus: Recruiting, Estimated PCD: 2027-06-01
Clinical trial
Multi-Centre, Placebo-Controlled, Phase 2 Study of Etripamil Nasal Spray (NS) for the Reduction of Ventricular Rate in Patients With Atrial Fibrillation.Status: Completed, Estimated PCD: 2023-08-03
Clinical trial
Multi-Centre, Open-Label, Safety Study of Etripamil Nasal Spray in Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia The NODE-302 Trial (Extension of NODE-301)Status: Terminated, Estimated PCD: 2020-11-13
Clinical trial
The NODE-303 Study: Multi-Centre, Multi-National,Open Label, Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia.Status: Completed, Estimated PCD: 2023-01-26